Rectal Diazepam for Intravesical Bladder Cancer Treatment Tolerance

Evidence Against Benzodiazepine Use in This Context

The American Urological Association guidelines make no mention of anxiolytics or benzodiazepines for improving tolerance of intravesical therapy in patients with non-muscle invasive bladder cancer 2, 3, 4, 5, 6
The Enhanced Recovery After Surgery Society states that long-acting benzodiazepines cause psycho-motor impairment during the postoperative period, which can impair mobilization and direct participation in elderly patients (>60 years) undergoing pelvic procedures 1
Long-acting benzodiazepines like diazepam are associated with cognitive dysfunction and delirium after surgery in elderly patients (>60 years), and are explicitly not indicated in this population 1

Patient education is the primary intervention to improve tolerance of intravesical therapy, as patients usually tolerate procedures better when they know what to expect, according to the National Comprehensive Cancer Network 7
Anxiolytics should be given preemptively for control of procedure-related anxiety when feasible, but this refers to short-acting agents in appropriate populations, not rectal diazepam in elderly patients, as recommended by the National Comprehensive Cancer Network 7
Supplemental doses of analgesics should be given in anticipation of procedure-related pain to improve tolerance of intravesical therapy, according to the National Comprehensive Cancer Network 7

Lower urinary tract symptoms (frequency, urgency, dysuria) are the most common side effects of intravesical therapy, occurring in 22-57% of patients depending on the regimen used, according to the American Urological Association 4, 5
Local symptoms such as hematuria, bladder pain, and prostatitis are common and similar across all intravesical treatments, as reported by the American Urological Association 2, 4
Systemic complications including fever/chills/flu symptoms are more common with BCG than chemotherapy regimens, according to the American Urological Association 2, 4, 5

Benzodiazepines cause respiratory depression, particularly when combined with opioids, which dramatically increases respiratory depression risk requiring at least 20% dose reduction of both agents, as warned by the Clinical Nutrition journal 8
In elderly, frail, or COPD patients, maximum doses of benzodiazepines should be reduced to 0.5-1 mg per dose due to synergistic respiratory depression risk, as recommended by the Clinical Nutrition journal 8
Diazepam requires dose reduction of at least 20% in patients with hepatic or renal impairment due to reduced clearance, as cautioned by the Praxis Medical Insights 8
Long-acting benzodiazepines have no advantages and are specifically discouraged in the perioperative setting due to risks of cognitive dysfunction and delirium, as stated by the Clinical Nutrition journal 1